Search Results for: PTPRF

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
JUP junction plakoglobin
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • Neutrophil degranulation
  • Keratinization
  • Formation of the cornified envelope
  • Zinc
  • Zinc acetate
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC)
  • Naxos disease and Carvajal syndrome
LACTB lactamase beta
LCK LCK proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Nef Mediated CD4 Down-regulation
  • Downstream TCR signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • PD-1 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Interleukin-2 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Dasatinib
  • AP-22408
  • Staurosporine
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
  • 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
  • N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
  • Ponatinib
  • Nintedanib
  • Fostamatinib
  • Zanubrutinib
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
LDHA lactate dehydrogenase A
  • Pyruvate metabolism
  • NADH
  • Etheno-NAD
  • Nicotinamide
  • Oxamic Acid
  • Stiripentol
  • Copper
  • Artenimol
LDHB lactate dehydrogenase B
  • Pyruvate metabolism
  • NADH
  • 4-Hydroxy-1,2,5-oxadiazole-3-carboxylic acid
  • Oxamic Acid
  • Stiripentol
  • Artenimol
NCAN neurocan
  • A tetrasaccharide linker sequence is required for GAG synthesis
  • Chondroitin sulfate biosynthesis
  • Dermatan sulfate biosynthesis
  • CS/DS degradation
  • ECM proteoglycans
  • Defective B4GALT7 causes EDS, progeroid type
  • Defective B3GAT3 causes JDSSDHD
  • Defective CHST3 causes SEDCJD
  • Defective CHST14 causes EDS, musculocontractural type
  • Defective CHSY1 causes TPBS
  • L1CAM interactions
  • NCAM1 interactions
  • Defective B3GALT6 causes EDSP2 and SEMDJL1
  • Beta-D-Glucose
  • Thiodigalactoside
  • Hyaluronic acid
NID1 nidogen 1
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Laminin interactions
  • Laminin interactions
  • Urokinase
PPFIA1 PTPRF interacting protein alpha 1
  • Serotonin Neurotransmitter Release Cycle
  • Norepinephrine Neurotransmitter Release Cycle
  • Glutamate Neurotransmitter Release Cycle
  • Dopamine Neurotransmitter Release Cycle
  • Acetylcholine Neurotransmitter Release Cycle
  • Receptor-type tyrosine-protein phosphatases
PPFIA2 PTPRF interacting protein alpha 2
  • Serotonin Neurotransmitter Release Cycle
  • Norepinephrine Neurotransmitter Release Cycle
  • Glutamate Neurotransmitter Release Cycle
  • Dopamine Neurotransmitter Release Cycle
  • Acetylcholine Neurotransmitter Release Cycle
  • Receptor-type tyrosine-protein phosphatases
PPFIA3 PTPRF interacting protein alpha 3
  • Serotonin Neurotransmitter Release Cycle
  • Norepinephrine Neurotransmitter Release Cycle
  • Glutamate Neurotransmitter Release Cycle
  • Dopamine Neurotransmitter Release Cycle
  • Acetylcholine Neurotransmitter Release Cycle
  • Receptor-type tyrosine-protein phosphatases
PRPF40A pre-mRNA processing factor 40 homolog A
  • mRNA Splicing - Major Pathway
PTPRA protein tyrosine phosphatase receptor type A
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
PTPRD protein tyrosine phosphatase receptor type D
  • Receptor-type tyrosine-protein phosphatases
  • Synaptic adhesion-like molecules
PTPRZ1 protein tyrosine phosphatase receptor type Z1
  • Other interleukin signaling
RAP1GDS1 Rap1 GTPase-GDP dissociation stimulator 1
RET ret proto-oncogene
  • RAF/MAP kinase cascade
  • RET signaling
  • Sorafenib
  • 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Vandetanib
  • Cabozantinib
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Fostamatinib
  • Amuvatinib
  • Selpercatinib
  • Pralsetinib
  • Hirschsprung disease (HD)
  • Renal agenesis and Renal adysplasia
  • Thyroid cancer
  • Congenital central hypoventilation syndrome (CCHS)
RHOA ras homolog family member A
  • GPVI-mediated activation cascade
  • Axonal growth inhibition (RHOA activation)
  • Rho GTPase cycle
  • PI3K/AKT activation
  • Axonal growth stimulation
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • G beta:gamma signalling through PI3Kgamma
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • PCP/CE pathway
  • G alpha (12/13) signalling events
  • Sema4D mediated inhibition of cell attachment and migration
  • Sema4D induced cell migration and growth-cone collapse
  • Sema4D induced cell migration and growth-cone collapse
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases activate PKNs
  • RHO GTPases activate CIT
  • RHO GTPases activate CIT
  • RHO GTPases activate KTN1
  • RHO GTPases Activate ROCKs
  • RHO GTPases Activate ROCKs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Rhotekin and Rhophilins
  • RHO GTPases Activate Rhotekin and Rhophilins
  • Ovarian tumor domain proteases
  • ERBB2 Regulates Cell Motility
  • Neutrophil degranulation
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • SLIT2:ROBO1 increases RHOA activity
  • Guanosine-5'-Diphosphate
ROCK2 Rho associated coiled-coil containing protein kinase 2
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • G alpha (12/13) signalling events
  • Sema4D induced cell migration and growth-cone collapse
  • Sema4D induced cell migration and growth-cone collapse
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate ROCKs
  • RHO GTPases Activate ROCKs
  • RHOBTB1 GTPase cycle
  • Potential therapeutics for SARS
  • Fasudil
  • Y-27632
  • Fostamatinib
  • Ripasudil
  • Netarsudil
SEMG1 semenogelin 1
  • Antimicrobial peptides
  • Amyloid fiber formation
  • Zinc
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
SEMG2 semenogelin 2
  • Zinc chloride
  • Zinc sulfate, unspecified form

Page 3 out of 4 pages